Review decision – November 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA367; Vortioxetine for treating major depressive disorder.
There is no new clinical effectiveness or cost data which would warrant reconsideration of the existing recommendations. The marketing authorisation and price of vortioxetine has not changed. It is therefore proposed that technology appraisal guidance TA367 is transferred to the ‘static guidance list’.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA367 will move to the ‘static list’ of technology appraisals.
This page was last updated: 30 November 2018